Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Moreover, the outlook for Syfovre is not promising ... Begin your TipRanks Premium journey today. Apellis Pharmaceuticals (APLS) Company Description: Apellis Pharmaceuticals, Inc. is a clinical-stage ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

Apellis is well positioned for future growth. We remain confident in our long-term strategy and the significant opportunities ahead.” Generated $152.0 million in SYFOVRE U.S. net product revenue ...

Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...